|
Volumn 94, Issue 5, 2002, Pages 329-330
|
Direct-to-consumer marketing: How has it fared?
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIASTHMATIC AGENT;
ANTIDIABETIC AGENT;
TAMOXIFEN;
TAMOXIFEN CITRATE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ADVERTIZING;
ASTHMA;
BREAST CANCER;
CONSULTATION;
CONTROLLED STUDY;
DIABETES MELLITUS;
DOCTOR PATIENT RELATION;
DRUG CHOICE;
DRUG COST;
DRUG INFORMATION;
DRUG MARKETING;
DRUG MONITORING;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN RIGHTS;
NOTE;
POLICY;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
|
EID: 0037029125
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.5.329 Document Type: Note |
Times cited : (17)
|
References (0)
|